Administration of Human Chorionic Gonadotrophin Before Secretory Transformation of Frozen-thawed Embryo Transfer Cycles

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05340010

Enrollment

180

Registered

2022-04-21

Start date

2020-01-01

Completion date

2022-07-30

Last updated

2022-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

FET, Frozen-thawed Embryo Transfe, hCG, Human Chorionic Gonadotrophin

Brief summary

Successful embryo implantation is complicated process that requires synchrony between good-quality embryos and receptive endometrium. Human chorionic gonadotropin (hCG), is one of the initial embryonic signals and the major embryoendometrial relationship regulator. This study will be conducted to to investigate the role of parenteral hCG used for the transfer of cryopreserved- thawed embryos with HRT cycles in the outcome of artificially prepared frozen embryo transfer (FET) cycles.

Interventions

DRUGHuman Chorionic Gonadotrophin Intramuscular injection 10.000 IU

From the 12th to 13th day of the cycle when endometrium reached the optimal thickness ≥8 mm, group 1 (hCG) will receive 10.000 IU hCG intramuscular injection in the morning then vaginal suppository progesterone 400 mg twice a day will be started in the afternoon

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 38 Years

Healthy volunteers

Inclusion criteria

* Patient age ≤ 38 years. * Normal 3D transvaginal ultrasound. * At least two good quality embryos cryopreserved by vitrification. * No GnRH agonists administration before FET cycle.

Exclusion criteria

* Endometriosis. * Uterine anomalies. * Evidence of hydrosalpinx by hystrosalpingography or ultrasound. * Evidence of immune disease, hematological or hormonal disorder.

Design outcomes

Primary

Measure	Time frame	Description
Live birth delivery rate (LBR)	7 months	Number of live births beyond 28 weeks of gestational age to the total number of FET cycles

Secondary

Measure	Time frame	Description
Clinical pregnancy rate	2 weeks after positive pregnancy test	number of cases with observed gestational sac with embryonic heartbeat detected by ultrasound two weeks after positive pregnancy to the totoal number of frozen embryo transfer cycles.
Implantation rate	2 weeks after positive pregnancy test	proportion of the number of gestational sacs to the number of embryos transferred
Miscarriage rate	20 weeks gestational age	number of lost before the 20th week of gestation to the number of clinical pregnancies

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026